Journal
AGING AND DISEASE
Volume 12, Issue 4, Pages 1070-1080Publisher
INT SOC AGING & DISEASE
DOI: 10.14336/AD.2021.0211
Keywords
epilepsy; drug-resistant epilepsy; neuromodulation; neurostimulation; VNS; RNS; DBS
Categories
Ask authors/readers for more resources
Epilepsy affects millions worldwide, with drug-resistant cases posing a challenge for surgical intervention. Neuromodulation therapies like VNS, RNS, and DBS may offer alternative treatment options for these patients.
Epilepsy affects approximately 70 million people worldwide, and it is a significant contributor to the global burden of neurological disorders. Despite the advent of new AEDs, drug resistant-epilepsy continues to affect 30-40% of PWE. Once identified as having drug-resistant epilepsy, these patients should be referred to a comprehensive epilepsy center for evaluation to establish if they are candidates for potential curative surgeries. Unfortunately, a large proportion of patients with drug-resistant epilepsy are poor surgical candidates due to a seizure focus located in eloquent cortex, multifocal epilepsy or inability to identify the zone of ictal onset. An alternative treatment modality for these patients is neuromodulation. Here we present the evidence, indications and safety considerations for the neuromodulation therapies in vagal nerve stimulation (VNS), responsive neurostimulation (RNS), or deep brain stimulation (DBS).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available